On Monday, Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) opened lower -4.58% from the last session, before settling in for the closing price of $7.86. Price fluctuations for BCRX have ranged from $4.03 to $9.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 169.91% over the past five years. Company’s average yearly earnings per share was noted 83.02% at the time writing. With a float of $197.24 million, this company’s outstanding shares have now reached $208.54 million.
Let’s look at the performance matrix of the company that is accounted for 580 employees. In terms of profitability, gross margin is 97.19%, operating margin of -0.54%, and the pretax margin is -19.29%.
Biocryst Pharmaceuticals Inc (BCRX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Biocryst Pharmaceuticals Inc is 5.61%, while institutional ownership is 78.44%. The most recent insider transaction that took place on Dec 13 ’24, was worth 52,780. In this transaction Director of this company sold 7,000 shares at a rate of $7.54, taking the stock ownership to the 86,638 shares. Before that another transaction happened on Dec 13 ’24, when Company’s Director proposed sale 7,000 for $7.51, making the entire transaction worth $52,584.
Biocryst Pharmaceuticals Inc (BCRX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 83.02% per share during the next fiscal year.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Trading Performance Indicators
Check out the current performance indicators for Biocryst Pharmaceuticals Inc (BCRX). In the past quarter, the stock posted a quick ratio of 2.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach 0.23 in one year’s time.
Technical Analysis of Biocryst Pharmaceuticals Inc (BCRX)
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) saw its 5-day average volume 2.31 million, a negative change from its year-to-date volume of 3.25 million. As of the previous 9 days, the stock’s Stochastic %D was 42.65%. Additionally, its Average True Range was 0.33.
During the past 100 days, Biocryst Pharmaceuticals Inc’s (BCRX) raw stochastic average was set at 24.67%, which indicates a significant increase from 8.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.28% in the past 14 days, which was lower than the 53.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.15, while its 200-day Moving Average is $7.65. Nevertheless, the first resistance level for the watch stands at $7.65 in the near term. At $7.80, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.90. If the price goes on to break the first support level at $7.41, it is likely to go to the next support level at $7.31. The third support level lies at $7.16 if the price breaches the second support level.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Key Stats
There are currently 208,960K shares outstanding in the company with a market cap of 1.57 billion. Presently, the company’s annual sales total 450,710 K according to its annual income of -88,880 K. Last quarter, the company’s sales amounted to 131,530 K and its income totaled -26,800 K.
